---
title: "Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293610647.md"
description: "Nuvectis Pharma (NASDAQ: NVCT) announced that its oral complement Factor B inhibitor, ciprocopan (NXP100), has received marketing approval from China's National Medicinal Products Administration. The drug is indicated for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors. This approval marks a significant milestone for the company's clinical-stage therapy."
datetime: "2026-07-23T11:33:11.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293610647.md)
  - [en](https://longbridge.com/en/news/293610647.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293610647.md)
---

# Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors

Nuvectis Pharma, Inc. (NASDAQ: NVCT), a biopharmaceutical company in Fort Lee, NJ, revealed that their new drug, ciprocopan (NXP100), an oral complement Factor B inhibitor, has been granted marketing approval by the National Medicinal Products Administration of China. This medication is intended for treating patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received treatment with complement inhibitors. Nuvectis specializes in developing therapies for complement-related conditions and oncology. This recent approval marks a significant milestone for the company's clinical-stage drug, providing a potentially effective treatment option for individuals with PNH.

### Related Stocks

- [NVCT.US](https://longbridge.com/en/quote/NVCT.US.md)

## Related News & Research

- [Nuvectis says China regulator approves ciprocopan for treatment-naive PNH patients](https://longbridge.com/en/news/293607988.md)
- [Zenas Biopharma posts corporate presentation on autoimmune disease pipeline, led by obexelimab program](https://longbridge.com/en/news/295789100.md)
- [Stoke Therapeutics’ Dravet Trial Tops Enrollment Target With Zero Dropouts](https://longbridge.com/en/news/296156348.md)
- [Argenx Shares Rise After Positive Results From Phase 3 Study of Efgartigimod](https://longbridge.com/en/news/296077357.md)
- [Mineralys Therapeutics publishes corporate presentation on lorundrostat for uncontrolled, resistant hypertension and cardiorenal diseases](https://longbridge.com/en/news/295607030.md)